STOCK TITAN

Medical Care Technologies Inc. (OTC PINK:MDCE) Advances AI Platform Accuracy for Early Melanoma Detection

(Positive)
Tags
AI

Medical Care Technologies (OTC PINK: MDCE) on May 5, 2026 said it is evaluating AI advances to improve early-stage dermatological imaging and longitudinal monitoring.

The company is integrating enhancements to its patent-pending imaging platform and beta app, focusing on deep learning, pattern recognition, temporal analysis, dataset expansion, and model refinement; the work remains in R&D.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – MDCE

+50.00%
+50.00% Session close to close

In the May 5 session, MDCE gained 50.00%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Emerging AI Imaging Capabilities Provide Dynamic Improvements in our Dermatological Analysis Accuracy

MESA, AZ / ACCESS Newswire / May 5, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), an emerging developer of AI-powered health and wellness technologies, today announced that it is actively evaluating and integrating new advances in artificial intelligence to support the development of high accuracy dermatological imaging solutions focused on early-stage skin condition detection.

Building upon its patent-pending imaging platform, the Company is exploring enhancements beyond it's current platform to enhance deep learning architectures, pattern recognition models, and temporal image analysis techniques designed to improve the identification and tracking of skin irregularities using the beta app on standard smart devices.

As part of this initiative, MDCE is assessing approaches that enable more accurate longitudinal dermatological monitoring, allowing for structured comparison of skin features over time. These advancements are intended to support more accurate detection of subtle variations in size, shape, and pigmentation that may not be easily identified through single-image analysis.

"Our focus is on continuously incorporating the latest advancements in AI to strengthen the capabilities and accuracy of our platform," said Marshall Perkins, CEO of Medical Care Technologies Inc. "Rather than relying on static models, we are exploring dynamic, data-driven systems that can evolve with improved datasets and emerging technologies."

The Company notes that this particular initiative remains in the research and development phase with an operational beta app in development, with ongoing efforts directed toward model refinement, dataset expansion, and evaluation of performance benchmarks. Future development pathways may include further validation processes and potential integration into broader AI-driven healthcare applications.

This effort reflects MDCE's broader strategy of building a scalable AI technology stack that can be applied across both consumer-facing and medically oriented use cases, including dermatological surveillance, wellness applications, and image-based health insights.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC Pink:MDCE) is focused on the development of artificial intelligence platforms across health, wellness, and diagnostic applications. The Company's patent-pending imaging technology is designed to enable real-time analysis across multiple verticals, including dietary, dermatological, and medical use cases.
For more information, visit: https://medicalcaretechnologies.com

Contact Information

Medical Care Technologies Inc.
Website: https://medicalcaretechnologies.com
Email: info@medicalcaretechnologies.com
Phone: 1-480-645-0750
Address: 1910 S Stapley Drive, Suite 221 Mesa, AZ 85204

Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future growth, marketing initiatives, user adoption, and business development. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that may impact results include, but are not limited to, market conditions, the effectiveness of marketing efforts, user engagement, and the Company's ability to execute its business strategy. Medical Care Technologies Inc. undertakes no obligation to update any forward-looking statements except as required by law.

Source: Medical Care Technologies Inc.



View the original press release on ACCESS Newswire

FAQ

What AI improvements is Medical Care Technologies (MDCE) pursuing for early melanoma detection?

MDCE is pursuing deep learning, pattern recognition, and temporal image analysis to detect subtle skin changes. According to the company, these approaches aim to improve longitudinal monitoring and identification of size, shape, and pigmentation variations using a beta app on standard smart devices.

Is the MDCE dermatology app commercially available or still in development?

The dermatology app from MDCE is still in research and development with an operational beta in progress. According to the company, ongoing work includes model refinement, dataset expansion, and performance benchmarking before any broader commercial validation or rollout.

How will MDCE validate the accuracy of its AI dermatological platform (MDCE)?

MDCE plans further validation processes and performance benchmarking as part of its R&D roadmap. According to the company, validation will follow model refinement and dataset expansion to assess accuracy for longitudinal dermatological monitoring and potential medical use cases.

What devices will MDCE's AI skin monitoring tools support for early melanoma detection (MDCE)?

MDCE intends the beta app to run on standard smart devices for image-based monitoring. According to the company, the platform is being developed to analyze device-captured images and support longitudinal comparison across routine consumer hardware.

What are the next development steps MDCE outlined for its AI imaging platform?

Next steps include dataset expansion, model refinement, benchmarking, and possible broader integration into healthcare applications. According to the company, these activities are part of scaling the patent-pending platform across consumer and medically oriented use cases.